课题基金 / 基金详情

Core E: Experimental Therapeutics Core

Core E: Experimental Therapeutics Core
核心 E:实验治疗核心
批准号:
9337371
负责人:
JAMES E BRADNER
金额:
$15.81万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
关键词:
Acute Graft Versus Host DiseaseAddressAllogenicAnalytical ChemistryAntibodiesAntigensB-LymphocytesBacteriaBiochemicalBiochemistry and Cellular BiologyBiologicalBiological ModelsBiologyCell physiologyCellsCharacteristicsChemicalsChromatinChronicClinicalClinical ResearchClinical assessmentsCollaborationsComputational BiologyDevelopmentDiseaseDrug effect disorderEpigenetic ProcessFibrosisGenetic TranscriptionGoalsHistocompatibility TestingHistonesHumanImmuneImmunoglobulinsImmunologicsImmunologyInflammationInflammatory ResponseInsectaInterdisciplinary StudyInvestigationInvestigational TherapiesLaboratoriesLeadershipMass Spectrum AnalysisMethodsModelingMolecularMorbidity - disease rateOrganic ChemistryOrganic SynthesisPathway interactionsPatientsPeptide SynthesisPeptidesPharmaceutical PreparationsPharmacologic SubstancePharmacologyPhasePre-Clinical ModelPreventionProductionProteinsReaderReagentRecombinant ProteinsResearchResearch InfrastructureResearch PersonnelS PhaseSeriesSignal PathwaySignal TransductionSolidSurface AntigensTechnologyTertiary Protein StructureTestingTherapeuticTherapeutic AgentsTherapeutic InterventionToxic effectTranslational ResearchTreatment EfficacyValidationYeastsbasechronic graft versus host diseaseclinical biomarkersclinical investigationclinical practiceclinical translationgraft vs host diseasehematopoietic cell transplantationimmunoregulationin vivoinhibitor/antagonistinnovationinsightinterdisciplinary approachmortalitynovelnovel therapeuticspeptide drugpre-clinicalprogramsprototyperesponsesmall moleculesynthetic peptidetherapeutic evaluationtooltranslational studytreatment strategy

项目摘要

项目成果

JAMES E BRADNER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Core E The discovery, characterization and development of novel therapeutic strategies to ameliorate the morbidity and mortality of graft-versus-host disease (GVHD) requires an interdisciplinary approach leveraging emerging biological insights and novel pharmacologic strategies. Already, this Program has successfully developed new and effective therapeutic interventions based on biological hypotheses tested in preclinical models of GVHD. To accelerate the pace of research and to more immediately connect the preclinical and clinical programs, we have created a new Experimental Therapeutics Core Laboratory. The goals of the Core are (a) to provide immediate and unrestricted access to chemical probes, investigational agents and therapeutic substances for preclinical and biological assessment, (b) to derive chemical derivatives of active agents to address disclosed pharmacologic liabilities encountered in this research, as needed, (c) to provide high-purity synthetic peptides allowing the validation of surface antigens and (d) to purify recombinant proteins or protein domains for the characterization of putative alloreactive antibodies. Beyond these technical objectives, the leadership and staff of the Experimental Therapeutics Core Laboratory will provide expertise in molecular pharmacology guiding selection and use of chemical tools alone or in combination in biological and translational studies proposed herein. As therapeutic agents enter human clinical investigation, the Core will contribute to the selection and assessment of clinical biomarkers of drug action. The completion of these objectives will require the development of new methods in organic synthesis, parallel solid-phase peptide synthesis, analytical chemistry, protein production and mass spectrometry. As such, the Core is located in a state-of-the-art chemical biology laboratory which possesses the infrastructure, expertise and technology required to complete the stated Aims and to integrate inter-programmatic activities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of Chromatin Signaling in Heart Failure by BET Bromodomain Proteins
  • 批准号:
    9042034
  • 项目类别:
  • 资助金额:
    $88.17万
  • 财政年份:
    2015
  • 负责人:
    JAMES E BRADNER
  • 依托单位:
Selective inhibition of BRDT for male contraception
  • 批准号:
    8528971
  • 项目类别:
  • 资助金额:
    $24.33万
  • 财政年份:
    2012
  • 负责人:
    JAMES E BRADNER
  • 依托单位:
Selective inhibition of BRDT for male contraception
  • 批准号:
    8549777
  • 项目类别:
  • 资助金额:
    $23.09万
  • 财政年份:
    2012
  • 负责人:
    JAMES E BRADNER
  • 依托单位:
Selective inhibition of BRDT for male contraception
  • 批准号:
    8692994
  • 项目类别:
  • 资助金额:
    $23.65万
  • 财政年份:
    2012
  • 负责人:
    JAMES E BRADNER
  • 依托单位:
海外基金